New Delhi, Nov 3 (PTI) Contract research, development and manufacturing organisation Nucelion Therapeutics on Monday said it has formally commenced operations.

A wholly-owned subsidiary of Bharat Biotech International, the company aims to support global life science innovators with high-quality, scalable process development and manufacturing solutions for advanced therapies, indicated for cancers, autoimmune disorders, and rare genetic disorders, the Hyderabad-based firm said in a statement.

"The future of pharmaceutical innovation will be biological; CGTs are a key vector. Our vision is to integrate advanced therapy platforms into India’s healthcare ecosystem, enabling equitable solutions for complex and rare diseases,” Nucelion Therapeutics Non-Executive Director Krishna Ella said.

Nu

See Full Page